--- https://www.has-sante.fr/portail/jcms/c_2779830/fr/ninlaro 2017 false false false France French treatment outcome ixazomib ixazomib ixazomib orphan drug production adult multiple myeloma antineoplastic combined chemotherapy protocols antineoplastic agents antineoplastic agents administration, oral proteasome inhibitors proteasome inhibitors dexamethasone survival analysis aged evaluation of the transparency committee boron compounds glycine boron compounds thalidomide thalidomide Lenalidomide
--- https://www.has-sante.fr/portail/jcms/c_2810355/fr/ninlaro 2017 false false false false France French evaluation of the transparency committee Ninlaro ixazomib boron compounds glycine
--- https://www.ema.europa.eu/medicines/human/EPAR/Ninlaro 2016 false false false United Kingdom French English treatment outcome syndication feed summary of product characteristics package leaflet drug evaluation ixazomib ixazomib ixazomib drug approval europe orphan drug production adult multiple myeloma antineoplastic combined chemotherapy protocols antineoplastic agents antineoplastic agents administration, oral proteasome inhibitors proteasome inhibitors risk assessment product surveillance, postmarketing drug monitoring dexamethasone continuity of patient care drug interactions pregnancy breast feeding survival analysis aged drug evaluation, preclinical IRd Regimen boron compounds glycine glycine boron compounds glycine thalidomide thalidomide Lenalidomide